the placebo group – Page 10 – Communicable Diseases Research

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

맹검 단계 완료 시 mRNA-1273 SARS-CoV-2 백신의 효능

Clinical Trial

Published on 2021-09-222022-09-25
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 신약개발, 임상, 진단,

Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis

Research Paper

Published on 2021-09-092022-10-04
Journal: EClinicalMedicine [Category] 임상,

[키워드] acute respiratory syndrome Administered age Anticoagulant Antiviral arginine clinical trial Comorbidities conducted confounder coronavirus coronavirus disease COVID-19 D-dimer decrease demonstrated double-blind duration of symptoms Effect Endothelial dysfunction Endothelium evaluated exhibited finding funding groups Hospitalization immune response IMPROVE In-hospital initial interim analysis interquartile range L-Arginine lymphocyte median Naple Nasopharyngeal swab not significantly different outcome parallel-group Patient patients patients hospitalized patients treated Placebo placebo-controlled placebo-controlled trial polymerase chain primary efficacy endpoint provided randomization Randomized reduce reduced reduction in Registered Respiratory Support Result reverse transcription RT-PCR SARS-CoV-2 secondary secondary outcome Serious Adverse Event severe COVID-19 shown significant difference significantly Standard therapy the placebo group Treatment Trial
[DOI] 10.1016/j.eclinm.2021.101125 PMC 바로가기 [Article Type] Research Paper

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

COVID-19 치료를 위한 SARS-CoV-2-중화 단일클론항체

Review

Published on 2021-09-022022-09-11
Journal: The Cochrane database of systematic reviews [Category] SARS, 변종, 임상,

[키워드] 95 % CI 95% CI 95% confidence interval Admission adverse event adverse events AEs all-cause mortality antibody approach average age B cell B cells bamlanivimab Blinding Casirivimab certainty certainty of evidence checked clinical Cochrane COVID-19 Study Register Combination combination therapy conducted coronavirus disease Coronavirus disease 2019 COVID-19 Data collection database death decrease dose Effectiveness etesevimab evaluated event Evidence excluded first test GRADE hospital Hospital admission Hospital admissions hospital discharge hospitalised Host Human identify Imdevimab IMV individual individuals with COVID-19 initial Intervention Invasive mechanical ventilation investigated lack life limitation mAb mAbs maintain moderate monoclonal antibodies monoclonal antibody Mortality NCT04427501 neutralising mAbs nine no effect non-hospitalised occurred outcome oxygen Oxygen requirement participant Participants patients with COVID-19 people with COVID-19 Placebo placebo group placebo treatment potential therapy progression Prophylactic provided Quality of life randomised controlled trial RCT reduce regdanvimab reported risk risk of bia risk ratio RoB2 SAE SAEs Sample size SARS-CoV-2 variant SARS-CoV-2 variants searched Selection Serious Adverse Event Serious Adverse Events severe symptom severe symptoms slight increase Sotrovimab submission Symptom systematic review target the placebo group treat treated Treatment treatment of COVID-19 usual care usual care alone
[DOI] 10.1002/14651858.CD013825.pub2 PMC 바로가기 [Article Type] Review

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

Randomized Controlled Trial

Published on 2021-09-012022-10-05
Journal: The Lancet. Respiratory Medicine [Category] Coronavirus, SARS, 임상,

[키워드] 1:1 95% CI adverse event adverse events alveolar Analysis assigned baseline block size cardiovascular disease center clinical benefit Clinical data clinical trial complication of COVID-19 concomitant treatment diabetes did not reduce died dose double-blind Effect Efficacy and safety eligible EU Clinical Trial EudraCT European foundation greater hazard ratio heart failure hospital hospitalised patient hypoxaemic respiratory failure Imatinib inhibitor initiative Invasive mechanical ventilation IQR Loading dose maintain malignancy management mechanical ventilation median median age medication Medicine modified intention-to-treat Mortality Netherlands not significantly different obesity oedema outcome Patient patients patients with COVID-19 peripheral oxygen saturation Placebo placebo-controlled platform Primary outcome pulmonary disease randomised Randomly receive receiving Registered required requiring supplemental oxygen RT-PCR test SARS-CoV-2 screened secondary Sex stratified supplemental oxygen survival the placebo group time Treatment two group union Ventilation was done were excluded with COVID-19
[DOI] 10.1016/S2213-2600(21)00237-X PMC 바로가기 [Article Type] Randomized Controlled Trial

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Clinical Trial

Published on 2021-09-012022-10-05
Journal: The lancet. Diabetes & endocrinology [Category] 임상,

[키워드] 1:1 95% CI acute illness adverse event affecting assigned AstraZeneca atherosclerotic benefit cardiometabolic risk factor cardiovascular disease Chronic kidney disease clinical recovery clinical status COVID-19 Critically ill Dapagliflozin death dose double-blind dysregulated hazard ratio heart failure hospitalised hypertension inhibitor intention-to-treat kidney medication multiorgan failure occurred organ organ dysfunction outcome outcomes Patient patients treated patients with COVID-19 phase 3 trial Placebo placebo-controlled placebo-controlled trial Primary outcome Protective randomised Randomly Registered reported risk reduction Safety Serious Adverse Events statistically significant the placebo group Treatment type 2 diabetes were assessed were excluded with COVID-19 worsened
[DOI] 10.1016/S2213-8587(21)00180-7 PMC 바로가기 [Article Type] Clinical Trial

Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study

Randomized Controlled Trial

Published on 2021-09-012022-10-05
Journal: American journal of otolaryngology [Category] 임상, 치료법,

Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients—a double-blind, placebo-controlled, clinical trial

Randomized Controlled Trial

Published on 2021-08-282022-10-04
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] acute respiratory syndrome Adverse adverse effect adverse event age analyzed Arm ARMS assessment Asymptomatic baseline blood biochemical breathlessness C-reactive protein clinical symptom clinical trial Coronavirus-2 cough COVID-19 COVID-19 patient CRP D-dimer diagnosed diarrhea discharge discharged disease double-blind Double-blinded RCT drug ECG Effect effective Efficacy Electrolyte enrolled evaluate event female ferritin Fever hospital Hospital stay ICU IL6 Inflammatory marker intensive care interleukin-6 Kaba Sura Kudineer Kruskal-Wallis test lactate dehydrogenase LDH Liver function main outcome measure male management mean value Medicines Mild Mild to moderate COVID-19 moderate Moderate COVID-19 Nilavembu kudineer not significantly different parameter participant Patient Placebo placebo-controlled primary outcome measure Public health intervention pursuit Randomized recorded recruited reduction in renal function respective treatment Result RT-PCR Safe SARS-CoV-2 SARS-CoV-2 viral load severe symptom Siddha Siddha Medicine significantly statistically significant reduction Sura Symptom symptomatic the patient the placebo group therapy three group Treatment viral epidemics Viral load virus vomiting were recorded while
[DOI] 10.1186/s13063-021-05478-0 PMC 바로가기 [Article Type] Randomized Controlled Trial

A Randomized, Single-Blind, Crossover Study Evaluating the Impact of OnabotulinumtoxinA Treatment on Mood and Appearance During the COVID-19 Pandemic

Randomized Controlled Trial

Published on 2021-08-132022-10-05
Journal: Aesthetic surgery journal [Category] SARS, 임상,

[키워드] administration Allergan amplify appearance both groups Botox caused COVID-19 COVID-19 pandemic crossover demonstrated Efficacy evaluate Evaluating groups Impact Ireland mood outbreak pandemic Patient placebo group Randomized receiving reported Satisfaction severe disease single-blind subject survey the placebo group Treatment treatment group unique
[DOI] 10.1093/asj/sjab196 PMC 바로가기 [Article Type] Randomized Controlled Trial

Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial

Randomized Controlled Trial

Published on 2021-08-102022-10-05
Journal: JAMA [Category] SARS, 임상,

[키워드] 95% CI absence all-cause hospitalization Antigen Azithromycin clinical clinical trial conducted COVID-19 COVID-19 symptom determine diagnostic dose Effect End points enrolled Enrollment greater Hospitalized individual ineligible interim analysis investigators likelihood matching placebo median age no significant difference nucleic acid amplification Older oral outcome Outpatient participant Placebo positive Prevalence Primary outcome proportion randomization Randomized safety monitoring committee SARS-CoV-2 SARS-COV-2 infection screened single dose Support Symptom the placebo group Treatment Trial white
[DOI] 10.1001/jama.2021.11517 PMC 바로가기 [Article Type] Randomized Controlled Trial

New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial)

Randomized Controlled Trial

Published on 2021-08-032022-10-04
Journal: BMJ Open [Category] SARS, 임상,

[키워드] 1:1 ACE Administered approval approved caused cell entry cleave clinical pharmacology clinical trial clinical trials Commission COVID-19 defined double-blind early stages effective Efficacy Endpoint Ethics ethics committee expected group HCQ Health health worker healthy host cell Hydroxychloroquine Infection Infectious diseases Intervention Local low dose Luis mechanism membrane Mortality New participant Patient peer-reviewed Placebo Preventive medicine professional progression prophylactic treatment Prophylaxis protease protection protocol randomised receptor reduction in regimen risk Sample size SARS-CoV-2 SARS-COV-2 infection serine 2 shown spike glycoprotein submitted the placebo group transmembrane two group virus
[DOI] 10.1136/bmjopen-2020-045190 PMC 바로가기 [Article Type] Randomized Controlled Trial